SVCM

Saturn V Capital Management Portfolio holdings

AUM $545M
1-Year Est. Return 361.94%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+361.94%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$456M
AUM Growth
+$209M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
26
New
Increased
Reduced
Closed

Top Buys

1 +$19.7M
2 +$13.9M
3 +$12.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$11.2M
5
ABVX
Abivax
ABVX
+$11M

Top Sells

1 +$28.5M
2 +$13.7M
3 +$7.31M
4
ASND icon
Ascendis Pharma
ASND
+$6.59M
5
ARGX icon
argenx
ARGX
+$5.67M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ABVX
1
Abivax
ABVX
$8.9B
$68M 14.92%
801,224
+178,745
AMLX icon
2
Amylyx Pharmaceuticals
AMLX
$1.57B
$62.6M 13.72%
4,604,878
+1,344,308
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$11.5B
$39.6M 8.69%
300,610
+93,658
DYN icon
4
Dyne Therapeutics
DYN
$2.47B
$33.8M 7.42%
2,674,469
+1,219,040
COGT icon
5
Cogent Biosciences
COGT
$6.09B
$29.1M 6.38%
2,025,041
-272,483
PCVX icon
6
Vaxcyte
PCVX
$8.63B
$28.4M 6.23%
788,441
+244,220
CELC icon
7
Celcuity
CELC
$5.04B
$23.4M 5.13%
473,828
-711,692
CGON icon
8
CG Oncology
CGON
$4.88B
$23.4M 5.12%
579,895
-6,752
IRON icon
9
Disc Medicine
IRON
$2.45B
$22.5M 4.94%
340,897
-55,218
PHVS icon
10
Pharvaris
PHVS
$1.77B
$22.1M 4.85%
+886,332
XENE icon
11
Xenon Pharmaceuticals
XENE
$3.36B
$20.2M 4.44%
503,701
+35,337
CNTA
12
Centessa Pharmaceuticals
CNTA
$3.89B
$17.8M 3.91%
734,539
-58,788
MRUS
13
DELISTED
Merus
MRUS
$17.3M 3.8%
184,135
-40,125
LENZ
14
LENZ Therapeutics
LENZ
$420M
$17.1M 3.76%
368,176
+25,864
OCUL icon
15
Ocular Therapeutix
OCUL
$2.35B
$13.5M 2.95%
1,151,686
+423,110
MNPR icon
16
Monopar Therapeutics
MNPR
$351M
$12.7M 2.78%
+155,370
NAMS icon
17
NewAmsterdam Pharma
NAMS
$3.64B
$4.36M 0.96%
153,147
-67,548
ARGX icon
18
argenx
ARGX
$46.6B
-10,285
ASND icon
19
Ascendis Pharma
ASND
$15.2B
-38,191
KALV icon
20
KalVista Pharmaceuticals
KALV
$797M
-62,793
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$1.26B
-290,784
NBIX icon
22
Neurocrine Biosciences
NBIX
$13.3B
-58,181
REPL icon
23
Replimune Group
REPL
$607M
-128,917
SLN
24
Silence Therapeutics
SLN
$273M
-34,737
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.94B
-500,551